基本情報

写真a

高山　和雄(タカヤマ　カズオ)

TAKAYAMA Kazuo


職名

教授

生年

1986年

研究室住所

M&Dタワー23階

研究室電話番号

03-5803-5820

メールアドレス

takayama.kazuo@tmd.ac.jp

ホームページ

https://www.ktakayama.com/

研究分野・キーワード

iPS細胞、オルガノイド、臓器チップ、ウイルス感染症、創薬

プロフィール

2006年4月～2010年3月　大阪大学薬学部薬科学科
2010年4月〜2012年3月　大阪大学大学院薬学研究科　修士課程
2012年4月〜2015年3月　大阪大学大学院薬学研究科　博士課程
2015年4月〜2018年1月 大阪大学大学院薬学研究科分子生物学分野　特任助教
2018年2月～2020年2月　大阪大学大学院薬学研究科分子生物学分野　助教
2020年3月～2025年3月 京都大学iPS細胞研究所　講師
2025年2月～現在　　　 東京科学大学総合研究院難治疾患研究所　教授

分野紹介URL

https://www.ktakayama.com/

このページの先頭へ▲

出身学校 【 表示 ／ 非表示 】

  • 大阪大学  薬学部  薬科学科  2010年03月  卒業

このページの先頭へ▲

出身大学院 【 表示 ／ 非表示 】

  • 大阪大学  薬学研究科  博士課程  2015年03月  修了

このページの先頭へ▲

取得学位 【 表示 ／ 非表示 】

  • 博士（薬科学）  大阪大学

このページの先頭へ▲

経歴(学内) 【 表示 ／ 非表示 】

  • 2025年02月
    -
    現在
    東京科学大学 教育研究組織 総合研究院 難治研・未来科学研究部門 人体模倣システム学分野 教授
このページの先頭へ▲

経歴(学外) 【 表示 ／ 非表示 】

  • 2015年04月
    -
    2018年01月
    大阪大学大学院薬学研究科 特任助教
  • 2018年02月
    -
    2020年02月
    大阪大学大学院薬学研究科 助教
  • 2020年03月
    -
    2025年03月
    京都大学iPS細胞研究所 講師
このページの先頭へ▲

所属学協会 【 表示 ／ 非表示 】

  • International Society for Stem Cell Research (ISSCR)

  • バイオインダストリー協会

  • 肝細胞研究会

  • 日本ウイルス学会

  • 日本再生医療学会

  • 日本組織培養学会

  • 日本動物実験代替法学会

  • 日本毒性学会

  • 日本分子生物学会

  • 日本薬学会

  • 日本薬物動態学会

  • 日本疾患幹細胞学会

▼全件表示

このページの先頭へ▲

委員歴 【 表示 ／ 非表示 】

  • 国立大学法人滋賀医科大学 ヒトES細胞使用研究倫理審査委員会
  • 一般社団法人　日本疾患幹細胞学会 理事
  • 一般社団法人　日本組織培養学会 理事
  • 一般社団法人　G2P-Japan 理事
このページの先頭へ▲

研究分野 【 表示 ／ 非表示 】

  • 生体医工学

このページの先頭へ▲
 

研究テーマ 【 表示 ／ 非表示 】

  • 人体模倣システムの開発と創薬応用

  • 仮想人体モデルの開発と感染症創薬への応用

このページの先頭へ▲

競争的資金等の研究課題 【 表示 ／ 非表示 】

  • 次世代の医療を開拓するヒト小腸組織チップの開発と応用

    文部科学省/日本学術振興会 : 2025年 - 2026年

  • 生体模倣デバイスを用いた腸運動異常を起点とする炎症スバイラルの解析

    文部科学省/日本学術振興会

  • 血管バリアに着目する新しい視点での重症感染症の病態・後遺症発症機構の解明と制御

    文部科学省/日本学術振興会

このページの先頭へ▲

論文・総説 【 表示 ／ 非表示 】

  1. Tsujino S, Tsuda M, Deguchi S, Ito J, Taha TY, Nasser H, Wang L, Rosecrans J, Suzuki R, Suzuki S, Yoshimatsu K, Ott M, Ikeda T, Sato K, Takayama K, Tanaka S, Tamura T, Fukuhara T, Genotype to Phenotype Japan (G2P-Japan) Consortium. A non-spike nucleocapsid R204P mutation in SARS-CoV-2 Omicron XEC enhances inflammation and pathogenicity. Nature communications. 2025.12; 17 (1): 735. ( PubMed, DOI )

  2. Nakata Y, Yamasaki M, Watanabe Y, Uriu K, Hashimoto R, Yamamoto T, Genotype to Phenotype Japan (G2P-Japan) Consortium, Sato K, Saito A, Takayama K. Mpox virus OPG175 negatively regulates viral replication by controlling Wnt signaling. iScience. 2025.12; 28 (12): 114105. ( PubMed, DOI )

  3. Nakata Y, Uriu K, Hashimoto R, Yamamoto T, Genotype to Phenotype Japan (G2P-Japan) Consortium, Saito A, Sato K, Takayama K. Mpox virus replicates in lung organoids without significantly affecting their cellular function. Biochemistry and biophysics reports. 2025.12; 44 102326. ( PubMed, DOI )

  4. Negoro R, Deguchi S, Yamazaki D, Takayama K, Fujita T. Genome edited intestine liver on a chip system for integrated intestinal hepatic drug absorption and metabolism evaluation. Scientific reports. 2025.11; 15 (1): 38609. ( PubMed, DOI )

  5. Hiroko Toyoda, Ayaka Nozue, Yuki Nishida, Yasuko Yakabe, Yasuhiko Aiki, Yukiko Ueyama-Toba, Kazuo Takayama, Hiroyuki Mizuguchi, Chihiro Mori, Yu-Suke Torisawa, Yoko Sakai, Takahiro Iwao, Tamihide Matsunaga, Shinichiro Horiuchi, Daiju Yamazaki, Seiichi Ishida, Nobuhiko Kojima, Kosuke Inamura, Yasuyuki Sakai, Masaki Nishikawa, Ikue Mihara, Takafumi Akabane, Yuzuru Ito. Considerations for developing CYP induction assays in hepatocytes: Insights from a multilaboratory study. Eur J Cell Biol. 2025.09; 104 (3): 151497. ( PubMed, DOI )

  6. Shuhei Tsujino, Masumi Tsuda, Naganori Nao, Kaho Okumura, Lei Wang, Yoshitaka Oda, Yume Mimura, Jingshu Li, Rina Hashimoto, Yasufumi Matsumura, Rigel Suzuki, Saori Suzuki, Kumiko Yoshimatsu, Miki Nagao, Jumpei Ito, Kazuo Takayama, Kei Sato, Keita Matsuno, Tomokazu Tamura, Shinya Tanaka, Takasuke Fukuhara, . Evolution of BA.2.86 to JN.1 reveals that functional changes in non-structural viral proteins are required for fitness of SARS-CoV-2. J Virol. 2025.09; e0090825. ( PubMed, DOI )

  7. Miguel Martí, Alba Cano-Vicent, Mercedes Cervera-Alamar, Rina Hashimoto, Kazuo Takayama, Ángel Serrano-Aroca. Multifunctional materials with potential antiviral applications in face masks, face shields, and hydrogels against mpox virus. Sci Rep. 2025.09; 15 (1): 32075. ( PubMed, DOI )

  8. Soichiro Hashimoto, Toshiro Hirai, Koki Ueda, Mako Kakihara, Nagisa Tokunoh, Chikako Ono, Yoshiharu Matsuura, Kazuo Takayama, Yasuo Yoshioka. Hypertonic intranasal vaccines gain nasal epithelia access to exert strong immunogenicity. Mucosal Immunol. 2025.08; 18 (4): 793-809. ( PubMed, DOI )

  9. Shuhei Higuchi, Yafei Liu, Jun Shimizu, Chikako Ono, Yumi Itoh, Wataru Nakai, Hui Jin, Kazuki Kishida, Kazuo Takayama, Toru Okamoto, Yoshiko Murakami, Taroh Kinoshita, Yoshiharu Matsuura, Tatsuo Shioda, Hisashi Arase. Evolutionary dynamics of heparan sulfate utilization by SARS-CoV-2. mBio. 2025.08; 16 (8): e0130325. ( PubMed, DOI )

  10. Jumana Khalil, Kosuke Miyauchi, Yosie Suzuki, Sewon Ki, Yasuyo Harada, Takanori Sasaki, Yuichiro Yamamoto, Rina Hashimoto, Takako Yamamoto, Masashi Matsuda, Haruhiko Koseki, Manabu Nakayama, Masayoshi Fukasawa, Takaji Wakita, Hideki Ueno, Kohji Noguchi, Kazuo Takayama, Masato Kubo. The Role of IL-4+ Memory T Cells in SARS-CoV-2 Booster Vaccination. Int Immunol. 2025.08; ( PubMed, DOI )

  11. Chunhui Tian, Zheng Ao, Jonas Cerneckis, Hongwei Cai, Lei Chen, Hengyao Niu, Kazuo Takayama, Jungsu Kim, Yanhong Shi, Mingxia Gu, Takahisa Kanekiyo, Feng Guo. Understanding monocyte-driven neuroinflammation in Alzheimer's disease using human cortical organoid microphysiological systems. Sci Adv. 2025.08; 11 (34): eadu2708. ( PubMed, DOI )

  12. Rina Hashimoto, Yukio Watanabe, Abeer Keshta, Masaya Sugiyama, Yuki Kitai, Ai Hirabayashi, Naoko Yasuhara, Shiho Morimoto, Ayaka Sakamoto, Yasufumi Matsumura, Hidekazu Nishimura, Takeshi Noda, Takuya Yamamoto, Miki Nagao, Makoto Takeda, Kazuo Takayama. Human iPS cell-derived respiratory organoids as a model for respiratory syncytial virus infection. Life Sci Alliance. 2025.07; 8 (7): ( PubMed, DOI )

  13. Yuki Kitai, Shohei Kojima, Aikeda Aishajiang, Miyuki Kawase, Oshi Watanabe, Haruka Yabukami, Rina Hashimoto, Yukiko Akahori, Hiroshi Katoh, Kazuo Takayama, Hidekazu Nishimura, Kazuya Shirato, Makoto Takeda. Changes in ORF4 of HCoV-229E under different culture conditions. J Gen Virol. 2025.07; 106 (7): ( PubMed, DOI )

  14. Fuki Yokoi, Sayaka Deguchi, Kazuo Takayama. Advancing intestinal disease research using gut-on-a-chip. Regen Ther. 2025.06; 29 541-550. ( PubMed, DOI )

  15. Malvin Leonardo Pardi, Kazuo Takayama, Hirohide Saito. SARS-CoV-2 Nsp1-Resistant Modified RNA for the Creation of Nsp1-Responsive Systems. ACS Synth Biol. 2025.06; 14 (6): 2386-2392. ( PubMed, DOI )

  16. Hiroshi Arakawa, Kazuo Takayama. Future direction of animal alternative/microphysiological systems in drug discovery and development. Drug Metab Pharmacokinet. 2025.04; 61 101479. ( PubMed, DOI )

  17. Sayaka Deguchi, Fuki Yokoi, Kazuo Takayama. Organoids and microphysiological systems for pharmaceutical research of viral respiratory infections. Drug Metab Pharmacokinet. 2025.02; 60 101041. ( PubMed, DOI )

  18. Masatoshi Kakizaki, Rina Hashimoto, Noriyo Nagata, Takuya Yamamoto, Takashi Okura, Hiroshi Katoh, Yuki Kitai, Yukiko Akahori, Kazuya Shirato, Akihide Ryo, Kazuo Takayama, Makoto Takeda. The respective roles of TMPRSS2 and cathepsins for SARS-CoV-2 infection in human respiratory organoids. J Virol. 2025.01; 99 (1): e0185324. ( PubMed, DOI )

  19. Yasufumi Matsumura, Masaki Yamamoto, Yusuke Tsuda, Koh Shinohara, Yasuhiro Tsuchido, Satomi Yukawa, Taro Noguchi, Kazuo Takayama, Miki Nagao. Epidemiology of respiratory viruses according to age group, 2023-24 winter season, Kyoto, Japan. Sci Rep. 2025.01; 15 (1): 924. ( PubMed, DOI )

  20. Junya Michibata, Yoshimasa Kawaguchi, Hisaaki Hirose, Akiko Eguchi, Sayaka Deguchi, Kazuo Takayama, Wei Xu, Takuro Niidome, Yoshihiro Sasaki, Kazunari Akiyoshi, Shiroh Futaki. Polysaccharide-Based Coacervate Microgel Bearing Cationic Peptides That Achieve Dynamic Cell-Membrane Structure Alteration and Facile Cytosolic Infusion of IgGs. Bioconjug Chem. 2024.12; 35 (12): 1888-1899. ( PubMed, DOI )

  21. Minoru Inoue, Kazuo Takayama, Rina Hashimoto, Masahiro Enomoto, Naoki Date, Akihiro Ohsumi, Takashi Mizowaki. Hyponatremia unleashes neutrophil extracellular traps elevating life-threatening pulmonary embolism risk. Proc Natl Acad Sci U S A. 2024.11; 121 (45): e2404947121. ( PubMed, DOI )

  22. Fuki Yokoi, Sayaka Deguchi, Yukio Watanabe, Kazuo Takayama. Establishment of an ulcerative colitis model using colon organoids derived from human induced pluripotent stem cells. iScience. 2024.10; 27 (10): 111049. ( PubMed, DOI )

  23. Masako Yamasaki, Wakana Saso, Takuya Yamamoto, Masayoshi Sato, Hiroko Takagi, Tetsuya Hasegawa, Yuji Kozakura, Hiroyuki Yokoi, Hirofumi Ohashi, Kana Tsuchimoto, Rina Hashimoto, Shuetsu Fukushi, Akihiko Uda, Masamichi Muramatsu, Kazuo Takayama, Ken Maeda, Yoshimasa Takahashi, Tsuyoshi Nagase, Koichi Watashi. Anti-SARS-CoV-2 gapmer antisense oligonucleotides targeting the main protease region of viral RNA. Antiviral Res. 2024.10; 230 105992. ( PubMed, DOI )

  24. Shuhei Tsujino, Sayaka Deguchi, Tomo Nomai, Miguel Padilla-Blanco, Arnon Plianchaisuk, Lei Wang, Mst Monira Begum, Keiya Uriu, Keita Mizuma, Naganori Nao, Isshu Kojima, Tomoya Tsubo, Jingshu Li, Yasufumi Matsumura, Miki Nagao, Yoshitaka Oda, Masumi Tsuda, Yuki Anraku, Shunsuke Kita, Hisano Yajima, Kaori Sasaki-Tabata, Ziyi Guo, Alfredo A Hinay, Kumiko Yoshimatsu, Yuki Yamamoto, Tetsuharu Nagamoto, Hiroyuki Asakura, Mami Nagashima, Kenji Sadamasu, Kazuhisa Yoshimura, Hesham Nasser, Michael Jonathan, Olivia Putri, Yoonjin Kim, Luo Chen, Rigel Suzuki, Tomokazu Tamura, Katsumi Maenaka, Takashi Irie, Keita Matsuno, Shinya Tanaka, Jumpei Ito, Terumasa Ikeda, Kazuo Takayama, Jiri Zahradnik, Takao Hashiguchi, Takasuke Fukuhara, Kei Sato, . Virological characteristics of the SARS-CoV-2 Omicron EG.5.1 variant. Microbiol Immunol. 2024.09; 68 (9): 305-330. ( PubMed, DOI )

  25. Sayaka Deguchi, Kaori Kosugi, Naoki Takeishi, Yukio Watanabe, Shiho Morimoto, Ryosuke Negoro, Fuki Yokoi, Hiroki Futatsusako, May Nakajima-Koyama, Mio Iwasaki, Takuya Yamamoto, Yoshiya Kawaguchi, Yu-Suke Torisawa, Kazuo Takayama. Construction of multilayered small intestine-like tissue by reproducing interstitial flow. Cell Stem Cell. 2024.09; 31 (9): 1315-1326.e8. ( PubMed, DOI )

  26. Mengyang Wang, Yuko Sasaki, Rena Sakagami, Tomotaka Minamikawa, Masahiro Tsuda, Ryohei Ueno, Sayaka Deguchi, Ryosuke Negoro, Kanako So, Yuriko Higuchi, Ryuji Yokokawa, Kazuo Takayama, Fumiyoshi Yamashita. Perfluoropolyether-Based Gut-Liver-on-a-Chip for the Evaluation of First-Pass Metabolism and Oral Bioavailability of Drugs. ACS Biomater Sci Eng. 2024.07; 10 (7): 4635-4644. ( PubMed, DOI )

  27. Shigeru Fujita, Arnon Plianchaisuk, Sayaka Deguchi, Hayato Ito, Naganori Nao, Lei Wang, Hesham Nasser, Tomokazu Tamura, Izumi Kimura, Yukie Kashima, Rigel Suzuki, Saori Suzuki, Izumi Kida, Masumi Tsuda, Yoshitaka Oda, Rina Hashimoto, Yukio Watanabe, Keiya Uriu, Daichi Yamasoba, Ziyi Guo, Alfredo A Hinay, Yusuke Kosugi, Luo Chen, Lin Pan, Yu Kaku, Hin Chu, Flora Donati, Sarah Temmam, Marc Eloit, Yuki Yamamoto, Tetsuharu Nagamoto, Hiroyuki Asakura, Mami Nagashima, Kenji Sadamasu, Kazuhisa Yoshimura, Yutaka Suzuki, , Jumpei Ito, Terumasa Ikeda, Shinya Tanaka, Keita Matsuno, Takasuke Fukuhara, Kazuo Takayama, Kei Sato. Virological characteristics of a SARS-CoV-2-related bat coronavirus, BANAL-20-236. EBioMedicine. 2024.06; 104 105181. ( PubMed, DOI )

  28. Hiroki Futatsusako, Rina Hashimoto, Masaki Yamamoto, Jumpei Ito, Yasufumi Matsumura, Hajime Yoshifuji, Kotaro Shirakawa, Akifumi Takaori-Kondo, , Kei Sato, Miki Nagao, Kazuo Takayama. Longitudinal analysis of genomic mutations in SARS-CoV-2 isolates from persistent COVID-19 patient. iScience. 2024.05; 27 (5): 109597. ( PubMed, DOI )

  29. Masato Tanaka, Keisuke Shirakura, Yui Takayama, Miki Μatsui, Yukio Watanabe, Takuya Yamamoto, Junya Takahashi, Shota Tanaka, Nobumasa Hino, Takefumi Doi, Masanori Obana, Yasushi Fujio, Kazuo Takayama, Yoshiaki Okada. Endothelial ROBO4 suppresses PTGS2/COX-2 expression and inflammatory diseases. Commun Biol. 2024.05; 7 (1): 599. ( PubMed, DOI )

  30. Atsushi Masui, Rina Hashimoto, Yasufumi Matsumura, Takuya Yamamoto, Miki Nagao, Takeshi Noda, Kazuo Takayama, Shimpei Gotoh. Micro-patterned culture of iPSC-derived alveolar and airway cells distinguishes SARS-CoV-2 variants. Stem Cell Reports. 2024.04; 19 (4): 545-561. ( PubMed, DOI )

  31. A general fluorescence off/on strategy for fluorogenic probes: Steric repulsion-induced twisted intramolecular charge transfer (sr-TICT). 2024.02; 10 (7): eadi8847. ( PubMed, DOI )

  32. Virological characteristics of the SARS-CoV-2 BA.2.86 variant. 2024.02; 32 (2): 170-180. ( PubMed, DOI )

  33. SARS-CoV-2-induced disruption of a vascular bed in a microphysiological system caused by type-I interferon from bronchial organoids. 2024.01; ( PubMed, DOI )

  34. Ryosuke Negoro, Ayu Ouchi, Sayaka Deguchi, Kazuo Takayama, Takuya Fujita. Refining Hepatocyte Models to Capture the Impact of CYP2D6*10 Utilizing a PITCh System. Biol Pharm Bull. 2024; 47 (8): 1422-1428. ( PubMed, DOI )

  35. Complement factor D targeting protects endotheliopathy in organoid and monkey models of COVID-19. 2023.10; 30 (10): 1315-1330. ( PubMed, DOI )

  36. Pluripotent stem cell-based therapies and their path to the clinic. 2023.08; 18 (8): 1547-1548. ( PubMed, DOI )

  37. Comparative pathogenicity of SARS-CoV-2 Omicron subvariants including BA.1, BA.2, and BA.5. 2023.07; 6 (1): 772. ( PubMed, DOI )

  38. Virological characterization of the 2022 outbreak-causing monkeypox virus using human keratinocytes and colon organoids. 2023.06; 95 (6): e28827. ( PubMed, DOI )

  39. Convergent evolution of SARS-CoV-2 Omicron subvariants leading to the emergence of BQ.1.1 variant. 2023.05; 14 (1): 2671. ( PubMed, DOI )

  40. Organ-on-a-chip models for elucidating the cellular biology of infectious diseases. 2023.05; 119504. ( PubMed, DOI )

  41. Virological characteristics of the SARS-CoV-2 XBB variant derived from recombination of two Omicron subvariants. 2023.05; 14 (1): 2800. ( PubMed, DOI )

  42. Evaluation of Broad Anti-Coronavirus Activity of Autophagy-Related Compounds Using Human Airway Organoids. 2023.04; 20 (4): 2276-2287. ( PubMed, DOI )

  43. Elucidation of the liver pathophysiology of COVID-19 patients using liver-on-a-chips. 2023.03; 2 (3): pgad029. ( PubMed, DOI )

  44. Design of a chimeric ACE-2/Fc-silent fusion protein with ultrahigh affinity and neutralizing capacity for SARS-CoV-2 variants. 2023.01; 6 (1): 59-74. ( PubMed, DOI )

  45. Upregulation of Robo4 expression by SMAD signaling suppresses vascular permeability and mortality in endotoxemia and COVID-19 models. 2023.01; 120 (3): e2213317120. ( PubMed, DOI )

  46. Cell response analysis in SARS-CoV-2 infected bronchial organoids 2022.12; 5 (1): 516. ( PubMed, DOI )

  47. Non-uniform aspects of the SARS-CoV-2 intraspecies evolution reopen question of its origin. 2022.12; 222 (Pt A): 972-993. ( PubMed, DOI )

  48. State-of-the-art liver disease research using liver-on-a-chip. 2022.12; 42 (1): 62. ( PubMed, DOI )

  49. Application of perfluoropolyether elastomers in microfluidic drug metabolism assays. 2022.11; 627 122253. ( PubMed, DOI )

  50. Exocyst complex component 2 is a potential host factor for SARS-CoV-2 infection. 2022.11; 25 (11): 105427. ( PubMed, DOI )

  51. Virological characteristics of the SARS-CoV-2 Omicron BA.2.75 variant. 2022.11; 30 (11): 1540-1555. ( PubMed, DOI )

  52. SARS-CoV-2 disrupts respiratory vascular barriers by suppressing Claudin-5 expression. 2022.09; 8 (38): eabo6783. ( PubMed, DOI )

  53. Generation of HepG2 Cells with High Expression of Multiple Drug-Metabolizing Enzymes for Drug Discovery Research Using a PITCh System. 2022.05; 11 (10): ( PubMed, DOI )

  54. Decellularized Organ-Derived Scaffold Is a Promising Carrier for Human Induced Pluripotent Stem Cells-Derived Hepatocytes. 2022.04; 11 (8): ( PubMed, DOI )

  55. Biocompatible Films of Calcium Alginate Inactivate Enveloped Viruses Such as SARS-CoV-2. 2022.04; 14 (7): ( PubMed, DOI )

  56. Establishment of a stable SARS-CoV-2 replicon system for application in high-throughput screening. 2022.03; 199 105268. ( PubMed, DOI )

  57. Gene Therapy for Neuropsychiatric Disorders: Potential Targets and Tools. 2022.03; ( PubMed, DOI )

  58. The importance of accessory protein variants in the pathogenicity of SARS-CoV-2. 2022.03; 717 109124. ( PubMed, DOI )

  59. Emergence of unique SARS-CoV-2 ORF10 variants and their impact on protein structure and function. 2022.01; 194 128-143. ( PubMed, DOI )

  60. An issue of concern: unique truncated ORF8 protein variants of SARS-CoV-2. 2022; 10 e13136. ( PubMed, DOI )

  61. Intestinal Permeability of Drugs in Caco-2 Cells Cultured in Microfluidic Devices. 2022; 45 (9): 1246-1253. ( PubMed, DOI )

  62. Therapeutic Potential of Cannabinoids on Tumor Microenvironment: A Molecular Switch in Neoplasia Transformation. 2022; 21 15347354221096766. ( PubMed, DOI )

  63. Clinical utility of novel biosensing platform: Diagnosis of coronavirus SARS-CoV-2 at point of care. 2021.12; 304 130612. ( PubMed, DOI )

  64. Dual inhibition of TMPRSS2 and Cathepsin Bprevents SARS-CoV-2 infection in iPS cells. 2021.12; 26 1107-1114. ( PubMed, DOI )

  65. Non-Woven Infection Prevention Fabrics Coated with Biobased Cranberry Extracts Inactivate Enveloped Viruses Such as SARS-CoV-2 and Multidrug-Resistant Bacteria. 2021.11; 22 (23): ( PubMed, DOI )

  66. Protective Face Masks: Current Status and Future Trends. 2021.11; ( PubMed, DOI )

  67. Antimicrobial Face Shield: Next Generation of Facial Protective Equipment against SARS-CoV-2 and Multidrug-Resistant Bacteria. 2021.09; 22 (17): ( PubMed, DOI )

  68. Implications derived from S-protein variants of SARS-CoV-2 from six continents. 2021.09; 191 934-955. ( PubMed, DOI )

  69. Generation of Tetrafluoroethylene-Propylene Elastomer-Based Microfluidic Devices for Drug Toxicity and Metabolism Studies. 2021.09; 6 (38): 24859-24865. ( PubMed, DOI )

  70. Autoimmunity roots of the thrombotic events after COVID-19 vaccination. 2021.09; 102941. ( PubMed, DOI )

  71. Antiviral Face Mask Functionalized with Solidified Hand Soap: Low-Cost Infection Prevention Clothing against Enveloped Viruses Such as SARS-CoV-2. 2021.09; 6 (36): 23495-23503. ( PubMed, DOI )

  72. Periodically aperiodic pattern of SARS-CoV-2 mutations underpins the uncertainty of its origin and evolution. 2021.09; 112092. ( PubMed, DOI )

  73. Potential Molecular Mechanisms of Rare Anti-Tumor Immune Response by SARS-CoV-2 in Isolated Cases of Lymphomas. 2021.09; 13 (10): ( PubMed, DOI )

  74. In Vitro Model for a Drug Assessment of Cytochrome P450 Family 3 Subfamily A Member 4 Substrates Using Human Induced Pluripotent Stem Cells and Genome Editing Technology. 2021.08; 5 (8): 1385-1399. ( PubMed, DOI )

  75. Usability of Polydimethylsiloxane-Based Microfluidic Devices in Pharmaceutical Research Using Human Hepatocytes. 2021.08; 7 (8): 3648-3657. ( PubMed, DOI )

  76. COVID-19 Vaccines and Thrombosis-Roadblock or Dead-End Street? 2021.07; 11 (7): ( PubMed, DOI )

  77. SARS-CoV-2 research using human pluripotent stem cells and organoids. 2021.07; 10 (11): 1491-1499. ( PubMed, DOI )

  78. The mechanism behind flaring/triggering of autoimmunity disorders associated with COVID-19. 2021.07; 20 (10): 102909. ( PubMed, DOI )

  79. Targeting LIN28: a new hope in prostate cancer theranostics. 2021.07; ( PubMed, DOI )

  80. A unique view of SARS-CoV-2 through the lens of ORF8 protein. 2021.06; 133 104380. ( PubMed, DOI )

  81. Generation of tetracycline-controllable CYP3A4-expressing Caco-2 cells by the piggyBac transposon system. 2021.06; 11 (1): 11670. ( PubMed, DOI )

  82. Carbon-Based Nanomaterials: Promising Antiviral Agents to Combat COVID-19 in the Microbial-Resistant Era. 2021.05; 15 (5): 8069-8086. ( PubMed, DOI )

  83. Modeling SARS-CoV-2 infection and its individual differences with ACE2-expressing human iPS cells. 2021.05; 24 (5): 102428. ( PubMed, DOI )

  84. Overview of key molecular and pharmacological targets for diabetes and associated diseases. 2021.05; 278 119632. ( PubMed, DOI )

  85. Asymmetric profiles of infection and innate immunological responses in human iPS cell-derived small intestinal epithelial-like cell monolayers following infection with mammalian reovirus. 2021.04; 296 198334. ( PubMed, DOI )

  86. Notable sequence homology of the ORF10 protein introspects the architecture of SARS-CoV-2. 2021.04; 181 801-809. ( PubMed, DOI )

  87. In Vivo Gene Expression Profile of Human Intestinal Epithelial Cells: From the Viewpoint of Drug Metabolism and Pharmacokinetics. 2021.03; 49 (3): 221-232. ( PubMed, DOI )

  88. Vinblastine treatment decreases the undifferentiated cell contamination of human iPSC-derived intestinal epithelial-like cells. 2021.03; 20 463-472. ( PubMed, DOI )

  89. Protective Face Mask Filter Capable of Inactivating SARS-CoV-2, and Methicillin-Resistant Staphylococcus aureus and Staphylococcus epidermidis. 2021.01; 13 (2): ( PubMed, DOI )

  90. Introductions to the Community: Early-Career Researchers in the Time of COVID-19. 2020.12; 27 (6): 853-855. ( PubMed, DOI )

  91. The structural basis of accelerated host cell entry by SARS-CoV-2†. 2020.12; ( PubMed, DOI )

  92. Possible Transmission Flow of SARS-CoV-2 Based on ACE2 Features. 2020.12; 25 (24): ( PubMed, DOI )

  93. Photoactivatable oncolytic adenovirus for optogenetic cancer therapy. 2020.07; 11 (7): 570. ( PubMed, DOI )

  94. Establishment of SLC15A1/PEPT1-Knockout Human-Induced Pluripotent Stem Cell Line for Intestinal Drug Absorption Studies. 2020.06; 17 49-57. ( PubMed, DOI )

  95. In Vitro and Animal Models for SARS-CoV-2 research. 2020.05; ( PubMed, DOI )

  96. Tolloid-Like 1 Negatively Regulates Hepatic Differentiation of Human Induced Pluripotent Stem Cells Through Transforming Growth Factor Beta Signaling. 2020.02; 4 (2): 255-267. ( PubMed, DOI )

  97. Comparison of commercially available media for hepatic differentiation and hepatocyte maintenance. 2020; 15 (2): e0229654. ( PubMed, DOI )

  98. Modeling of Hepatic Drug Metabolism and Responses in CYP2C19 Poor Metabolizer Using Genetically Manipulated Human iPS cells. 2019.06; 47 (6): 632-638. ( PubMed, DOI )

  99. FGF signal is not required for hepatoblast differentiation of human iPS cells. 2019.03; 9 (1): 3713. ( PubMed, DOI )

  100. Takayama K, Negoro R, Yamashita T, Kawai K, Ichikawa M, Mori T, Nakatsu N, Harada K, Ito S, Yamada H, Yamaura Y, Hirata K, Ishida S, Mizuguchi H. Generation of Human iPSC-Derived Intestinal Epithelial Cell Monolayers by CDX2 Transduction. Cellular and molecular gastroenterology and hepatology. 2019; 8 (3): 513-526. ( PubMed, DOI )

  101. Pharmaceutical Research for Inherited Metabolic Disorders of the Liver Using Human Induced Pluripotent Stem Cell and Genome Editing Technologies. 2019; 42 (3): 312-318. ( PubMed, DOI )

  102. Efficient Generation of Small Intestinal Epithelial-like Cells from Human iPSCs for Drug Absorption and Metabolism Studies. 2018.12; 11 (6): 1539-1550. ( PubMed, DOI )

  103. Enrichment of high-functioning human iPS cell-derived hepatocyte-like cells for pharmaceutical research. 2018.04; 161 24-32. ( PubMed, DOI )

  104. Nanaomycin A Treatment Promotes Hepatoblast Differentiation from Human iPS Cells. 2018.03; 27 (6): 405-414. ( PubMed, DOI )

  105. Billion-scale production of hepatocyte-like cells from human induced pluripotent stem cells. 2018.02; 496 (4): 1269-1275. ( PubMed, DOI )

  106. Human iPS Cell-based Liver-like Tissue Engineering at Extrahepatic Sites in Mice as a New Cell Therapy for Hemophilia B. 2018.02; 27 (2): 299-309. ( PubMed, DOI )

  107. Generation of Optogenetically Modified Adenovirus Vector for Spatiotemporally Controllable Gene Therapy. 2018.02; 13 (2): 449-454. ( PubMed, DOI )

  108. Generation of safe and therapeutically effective human induced pluripotent stem cell-derived hepatocyte-like cells for regenerative medicine. 2017.12; 1 (10): 1058-1069. ( PubMed, DOI )

  109. y Direct conversion of human fibroblasts into hepatocyte-like cells by ATF5, PROX1, FOXA2, FOXA3, and HNF4A transduction 2017.11; 7 (1): 16675. ( PubMed, DOI )

  110. Hepatitis C virus-induced innate immune responses in human iPS cell-derived hepatocyte-like cells 2017.10; 242 7-15. ( PubMed, DOI )

  111. Hepatocyte Nuclear Factor 4 Alpha Promotes Definitive Endoderm Differentiation from Human Induced Pluripotent Stem Cells 2017.08; 13 (4): 542-551. ( PubMed, DOI )

  112. Human ESC/iPSC-Derived Hepatocyte-like Cells Achieve Zone-Specific Hepatic Properties by Modulation of WNT Signaling 2017.06; 25 (6): 1420-1433. ( PubMed, DOI )

  113. Highly efficient biallelic genome editing of human ES/iPS cells using a CRISPR/Cas9 or TALEN system 2017.05; 45 (9): 5198-5207. ( PubMed, DOI )

  114. Human induced-pluripotent stem cell-derived hepatocyte-like cells as an in vitro model of human hepatitis B virus infection 2017.04; 7 45698. ( PubMed, DOI )

  115. Inhibition of CRISPR/Cas9-Mediated Genome Engineering by a Type I Interferon-Induced Reduction in Guide RNA Expression 2017.03; 40 (3): 272-277. ( PubMed, DOI )

  116. Isolation and expansion of human pluripotent stem cell-derived hepatic progenitor cells by growth factor defined serum-free culture conditions 2017.03; 352 (2): 333-345. ( PubMed, DOI )

  117. Generation of a bile salt export pump deficiency model using patient-specific induced pluripotent stem cell-derived hepatocyte-like cells 2017.02; 7 41806. ( PubMed, DOI )

  118. Generation of human pluripotent stem cell-derived hepatocyte-like cells for drug toxicity screening 2017.02; 32 (1): 12-20. ( PubMed, DOI )

  119. Kazuo Takayama, Daiju Yamazaki. [Preface]. Nihon Yakurigaku Zasshi. 2025; 160 (2): 86. ( PubMed, DOI )

  120. Rina Hashimoto, Atsushi Masui, Shimpei Gotoh, Kazuo Takayama. [Development of human iPS cell-derived alveolar and airway models using micropatterning plate for SARS-CoV-2 research]. Uirusu. 2024; 74 (1): 35-44. ( PubMed, DOI )

  121. [State-of-the-art in respiratory disease research using respiratory organoids]. 2023; 158 (1): 71-76. ( PubMed, DOI )

  122. Takayama K. [Pharmaceutical Research on Liver Diseases Using iPS Cell and Genome Editing Technologies]. Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan. 2019; 139 (10): 1219-1225. ( PubMed, DOI )

  123. Multiple mutations of SARS-CoV-2 Omicron BA.2 variant orchestrate its virological characteristics. 2023.10; ( PubMed, DOI )

  124. Would New SARS-CoV-2 Variants Change the War against COVID-19? 2022.04; ( DOI )

  125. SARS-CoV-2 infection triggers paracrine senescence and leads to a sustained senescence-associated inflammatory response 2022.02; 2 (2): 115-124. ( DOI )

  126. Generation of Hepatocytes from Human ES/iPS Cells for Regenerative Medicine 2021; 3-26. ( DOI )

  127. Establishment of MDR1-knockout human induced pluripotent stem cell line. 2020.02; ( PubMed, DOI )

  128. Generation of Human Induced Pluripotent Stem Cell-Derived Hepatocyte-Like Cells for Cellular Medicine. 2020.01; ( PubMed, DOI )

  129. Matoba N, Yamashita T, Takayama K, Sakurai F, Mizuguchi H. Optimal human iPS cell culture method for efficient hepatic differentiation. Differentiation; research in biological diversity. 2018.09; 104 13-21. ( PubMed, DOI )

▼全件表示

このページの先頭へ▲

講演・口頭発表等 【 表示 ／ 非表示 】

  1. Kazuo Takayama. Infectious disease research using organoids and organ-on-a-chip. 第5回ロート再生医療フォーラム 2025.09.19

  2. Kazuo Takayama. RESEARCH FOR VIRAL RESPIRATORY INFECTIONS USING ORGANOIDS AND ORGAN-ON-A-CHIP. ISSCR 2025 Annual Meeting 2025.06.13

  3. Kazuo Takayama. Human ES/iPS cell-derived respiratory models for virus research. 31st FAOBMB Conference & 2025 KSBMB International Conference 2025.05.21

  4. 高山和雄. オルガノイドと臓器チップを用いた感染症創薬研究. 第3回文理薬シンポジウム 2025.09.05

  5. 高山和雄. 腸管MPSの開発と応用. MPSシリーズウェビナー第3回 2025.08.07

  6. 高山和雄. ヒトiPS細胞から分化誘導した肝臓チップと腸管チップの開発と応用. 第26回TLO京都主催　大学発シーズ　マッチングセミナー 2025.07.11

  7. 高山和雄. iPS細胞やオルガノイド、臓器チップを用いた感染症研究. 第二回・近未来への招待状～ナイスステップな研究者2024からのメッセージ～ 2025.07.08

  8. 高山和雄. iPS細胞をつかったウイルス研究. 東京科学大学難治疾患研究所第40回市民公開講座 2025.06.27

  9. 高山和雄. iPS細胞とMPS技術によるヒト臓器機能再現の挑戦. リプロセルWebinar 2025.06.25

  10. 高山和雄. オルガノイド、どういうときに使うか？どうやって使うか？. 第19回ウイルス学キャンプ 2025.06.17

  11. 高山和雄. ヒトiPS細胞由来腸管MPSの開発と事業化. 幹細胞を用いた化学物質リスク情報共有化コンソーシアム2025年度年会 2025.05.30

  12. 高山和雄. Development of an intestinal model using pluripotent stem cells and organ-on-a-chip technology. 第22回幹細胞シンポジウム 2025.05.24

  13. 高山和雄. iPS細胞、オルガノイド、臓器チップを用いたヒト腸管モデルの開発. 日本農芸化学会2025年度大会 2025.03.07

  14. 高山和雄. 臓器チップを用いた感染症創薬. 防衛イノベーション科学技術研究所・ワークショップ 2025.02.19

▼全件表示

このページの先頭へ▲